Pharmaceuticals
ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting
SUZHOU, China and ROCKVILLE, MD., Nov. 4, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts on three clinical trials of the c...
2021-11-05 08:43
2892
Novavax Files COVID-19 Vaccine for Emergency Use Listing with World Health Organization
All modules required for regulatory review of Novavax vaccine, including CMC data, are now complete for WHO GAITHERSBURG, Md., Nov. 5, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infec...
2021-11-05 05:00
4070
I-Mab to Present Clinical Data of Lemzoparlimab in Combination with Rituximab in Non-Hodgkins's Lymphoma at ASH 2021
* Lemzoparlimab is a differentiated CD47 monoclonal antibody discovered by I-Mab and being developed in collaboration with AbbVie * Initial clinical results of lemzoparlimab in combination with rituximab in NHL will be presented at the ASH 2021 Annual Meeting * I-Mab to host a call for inves...
2021-11-04 21:00
2058
Alterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
MELBOURNE, Australia, Nov. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the publication of two preclinical studie...
2021-11-04 19:30
2190
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia
FLORENCE, Italy, Nov. 4, 2021 /PRNewswire/ -- The Menarini Group announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) to SEL24/MEN1703 for the treatment of Acute Myeloid Leukemia (AML). SEL24/MEN1703 is a first-in-class, orally available, dual PIM...
2021-11-04 18:32
2528
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
SAN FRANCISCO and SUZHOU, China, Nov. 4, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-11-04 17:00
4333
New progress of studies on Lianhua Qingwen's mechanism to fight against SARS-CoV-2
BEIJING, Nov. 4, 2021 /PRNewswire/ -- During the efforts to prevent and control the epidemic, "3 medicines and 3 prescriptions" are selected from traditional Chinese medicine inChina, including the representative medicine "Lianhua Qingwen ", produced by Yiling pharmaceutical, which has been widely...
2021-11-04 12:56
3041
Envirotainer Opens New station in Guangzhou, China
STOCKHOLM, Nov. 4, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that they are opening a new station inGuangzhou, China to provide ground handling of container types RKN e1 and RAP e2. Envirot...
2021-11-04 10:39
2258
Kazia Enrols First Patient to EVT801 Phase I Clinical Trial
SYDNEY, Nov. 4, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec S...
2021-11-04 08:38
3651
Sensational artemisinin-piperaquine for treatment of COVID-19 in prospect
GUANGZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Artequick artemisinin and piperaquine tablets have once again become buzzwords across the globe, as most recently, their effectiveness in treating COVID-19 was hotly debated by live streamers on overseas social media and we media platforms. These dru...
2021-11-03 22:42
2557
TransThera Receives Fast Track Designation from FDA for its Core Product TT-00420 to Treat Cholangiocarcinoma
NANJING, China, Nov. 3, 2021 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative small molecule drug therapies for oncology, inflammatory and cardiovascular diseases, announced that the U.S. Food and Drug...
2021-11-03 22:00
1900
ERT and Bioclinica become Clario, The Leading Technology Solutions Company for Clinical Trial Innovation and Evidence
PHILADELPHIA, Nov. 3, 2021 /PRNewswire/ -- ERT, the global clinical endpoint technology leader, today announced that following its early Q2 merger with Bioclinica, a technological and scientific leader in medical imaging, the combined company is renamed Clario. Clario is a technology company tha...
2021-11-03 21:33
3751
Standigm Files PCT Patent Application of AI-driven Repurposed Drugs for Primary Mitochondrial Disease
SEOUL, South Korea, Nov. 3, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had filed PCT ("Patent Cooperation Treaty") patent application covering AI-driven repurposed drugs for primary m...
2021-11-03 21:00
2054
I-Mab Announces Upcoming Participation at November Conferences
SHANGHAI and GAITHERSBURG, Md., Nov. 3, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced its participation in the following conferences in Novemb...
2021-11-03 20:00
1768
BioKangtai's adenovirus vector COVID-19 vaccine obtained EUA in Indonesia
SHENZHEN, China, Nov. 3, 2021 /PRNewswire/ -- As reported by Indonesian National Agency of Drug and Food Control (BPOM), BPOM grants the Emergency Use Authorization (EUA) for COVID-19 Vaccine (ChAdOx1-S[recombinant])/KconecaVac manufactured by Shenzhen Kangtai Biological Products Co., Ltd. It is ...
2021-11-03 19:02
2097
Tabernacle Health Group Launches Revolutionary Immunity Booster!
SINGAPORE, Nov. 3, 2021 /PRNewswire/ -- As a result of the pandemic, boosting one's immune system has never been more crucial. Consisting of numerous chemicals, cells, proteins, and tissues that work together, the immune system is responsible for creating, storing, and distributing white blood ce...
2021-11-03 10:00
2723
Kintor Pharma Doses First Patient in Clinical Trial of ALK-1 in Combination with KN046 In Advanced or Refractory Solid Tumors
SUZHOU, China, Nov. 3, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company has enrolled and dosed its first patient with advanced...
2021-11-03 08:32
2549
Daewoong's "Leaps and Bounds" Q3 Performance, Exceeds KRW 20B in Operating Income for Three Consecutive Quarters
* Advancement of Nabota and prescriptions... KRW 290.6B sales and KRW 22.7B operating income * Expanding growth momentum with the release of Fexuprazan in Korea and Nabota inEurope next year SEOUL, South Korea, Nov. 2, 2021 /PRNewswire/ -- Daewoong Pharmaceutical (Daewoong) (CEOSengho Jeon) a...
2021-11-02 21:00
2043
PD-1/VEGF Bi-Specific Antibody (AK112) Obtained Approval to Initiate a Phase II Clinical Trial for Monotherapy or Combined Chemotherapy Neoadjuvant/Adjuvant Therapy of Resectable Non-Small Cell Lung Cancer
HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that AK112 (PD-1/VEGF bi-specific antibody), the novel immuno-oncology drug independently developed by the Company, obtained approval from the Center for Drug Evaluation (CDE) of the National Medical Products Ad...
2021-11-02 11:53
2220
Antengene Granted IND Approval in China for the Phase Ib Study of ATG-008 (Onatasertib) in Combination with ATG-010 (Selinexor) in Patients with Diffuse Large B-Cell Lymphoma
SHANGHAI and HONG KONG, Nov. 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-11-02 08:30
3960
Week's Top Stories
Most Reposted
Sustainable Tourism Impact Fund Expands Investments Across Southeast Asia
[Picked up by 309 media titles]
2026-04-03 11:30
Visa cements global K-pop connection as Worldwide Tour Sponsor for "BTS WORLD TOUR 'ARIRANG'"
[Picked up by 306 media titles]
2026-04-06 10:00
UTP Advances Across Key Disciplines in QS World University Rankings By Subject 2026 - Petroleum Engineering Among World's Top 10
[Picked up by 297 media titles]
2026-04-06 16:46
Marriott Bonvoy Returns as an Official Partner of the Cathay/HSBC Hong Kong Sevens 2026
[Picked up by 290 media titles]
2026-04-02 18:13
OneQode, Hitachi Vantara & Cylix Form Strategic Alliance to Launch Sovereign AI Factory Initiative
[Picked up by 281 media titles]
2026-04-08 08:00
Most Read
NYSE Content Update: Versigent To Ring Opening Bell As its Shares Debut for Trade
2026-04-01 22:44
6197
LightInTheBox Files 2025 Annual Report on Form 20-F
2026-04-02 20:00
6050
